01:58 , Oct 4, 2014 |  BC Extra  |  Politics & Policy

GPhA disputes lawmakers on generic prices

The Generic Pharmaceutical Association (GPhA) challenged data cited by members of Congress who are launching an investigation into generic drug prices. Sen. Bernie Sanders (I-Vt.) and Rep. Elijah Cummings (D-Md.) announced their investigation on Thursday,...
07:00 , Apr 14, 2014 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes...
07:00 , Mar 10, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Endo International plc (NASDAQ:ENDP; TSX:ENL) was off $6.06 to $73.76 last week after FDA approved a resubmitted NDA for Aveed testosterone to treat male hypogonadism. The company said it plans to launch the...
00:43 , Mar 8, 2014 |  BC Extra  |  Financial News

Flamel raises $105.3 million in follow-on

Drug delivery play Flamel Technologies S.A. (NASDAQ:FLML) raised $105.3 million through the sale of 10.8 million ADSs at $9.75 in a follow-on underwritten by JMP Securities; SunTrust; Ladenburg Thalmann; Roth Capital Partners; and Summer Street...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Financial News

Flamel completes debt financing

Flamel Technologies S.A. (NASDAQ:FLML), Lyon, France   Business: Drug delivery   Date completed: 12/4/13   Type: Debt financing   Raised: $5 million   Investor: Broadfin Capital   Note: Flamel drew down $5 million of a...
07:00 , Jun 10, 2013 |  BC Week In Review  |  Clinical News

Bloxiverz neostigmine methylsulfate regulatory update

FDA approved an NDA for Bloxiverz neostigmine methylsulfate from Flamel to reverse the effects of non-depolarizing neuromuscular blocking agents after surgery. Flamel expects to launch the cholinesterase inhibitor next month in 0.5 and 1.0 mg/mL...
07:00 , Jun 10, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) gained $0.24 to $19.79 on Friday after partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) submitted a Type II variation application to EMA to expand the European label of Rienso ferumoxytol...